Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04920318
Other study ID # 2103570362
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 30, 2021
Est. completion date June 15, 2026

Study information

Verified date September 2023
Source University of Arizona
Contact Aneta Kielar, PhD
Phone 15204883791
Email akielar@email.arizona.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.


Description:

Primary Progressive Aphasia (PPA) is a neurodegenerative disorder that selectively affects language comprehension and/or production, with initial preservation of other cognitive domains. As tDCS has not been extensively studied in PPA, the investigators will measure both short- and long-term effects of stimulation in patients with this neurodegenerative disorder that affects specific language regions. Previous research suggests that neurostimulation with tDCS can safely induce changes in neural plasticity that can lead to long-term restoration of synaptic function. Thus, individually targeted stimulation to structurally preserved but dysfunctional regions may be able to produce behavioral improvements in primary progressive aphasia (PPA). TDCS is a method of stimulating the brain that does not require any sedation or surgery. TDCS is a technique that sends a weak electrical current through the scalp to stimulate the brain areas below. The information gained from this research study will aid in the development of therapies to improve language in people with neurological conditions that affect language use. TDCS will be applied over the activated area identified with the functional magnetic resonance imaging (fMRI) fMRI-localizer task. This approach will allow for individually optimized tDCS electrode placement. It will also account for potential inter-participant variability in the brain atrophy and language organization Summary of study sequence and procedures: Week 1: Baseline screening, language testing, one event-related brain potential (EEG-ERP) session Weeks 2: fMRI session to determine most effective treatment Weeks 3-4: tDCS with Language Treatment Part 1 Weeks 5 and 6: rest-period, post-treatment assessment Weeks 7 to 8: TDCS with Language Treatment Part 2 Weeks 9 and 10: rest period, post-treatment assessment 2-month follow-up, language assessment, one MRI scan, one EEG-ERP session


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 15, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria: - diagnosed with PPA by neurologist or speech-language pathologist - speech-language deficit arising from PPA - native speaker of English Language or equivalent - adequate vision (normal or corrected to normal) - adequate hearing Exclusion Criteria: - meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders. - highly magnetizable metallic implants, including certain dental work - neurological disorders besides the ones of interest for the study (e.g., epilepsy) - Multiple Sclerosis - Parkinson's Disease - contraindications for MRI - pacemakers - metallic cardiac pumps - valves - magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field. - clinically significant claustrophobia - severe systemic disease (e.g., renal failure) - poor health - pregnancy - epileptic activity in the past 12 months - family history of epilepsy or other seizure disorders - brain surgery in the past - metallic skull plates or implants - skin lesions or skull damage - excessive use of alcohol or drugs - premorbid psychiatric disease affecting communication - severe non-linguistic cognitive disturbances impeding language therapy

Study Design


Intervention

Combination Product:
tDCS + language therapy
In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
sham TDCS + language therapy
sham control will be applied with language therapy to the same regions as active TDCS.

Locations

Country Name City State
United States University of Arizona Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change from baseline scores on the Arizona Phonological Battery Mean change from baseline scores on the Arizona Phonological Battery: Minimum score = 0; maximum = 100%; higher scores indicate better outcome through study completion, an average of 1 year
Primary Mean change from baseline scores on the naming task Mean change from baseline scores on the Boston Naming Test: Min score = 0; Max = 60; higher scores indicate better outcome through study completion, an average of 1 year
Primary Mean change from baseline scores on the language probe task before and after each session change on on the probe task from before the session; Min =0; Max = 100%; higher scores indicate better outcome through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT04957537 - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia N/A
Completed NCT04045990 - Network Modulation in Alzheimer's Disease N/A
Recruiting NCT05443633 - Enhancing Language Function in Aphasia N/A
Completed NCT05860647 - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia N/A
Recruiting NCT03887481 - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA N/A
Completed NCT03728582 - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Completed NCT02541097 - Preventing Language Decline in Dementia N/A
Recruiting NCT00537004 - Language in Primary Progressive Aphasia
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Active, not recruiting NCT05742698 - Nabilone for Agitation in Frontotemporal Dementia Phase 2
Completed NCT02439853 - Communication Bridge Speech Therapy Research Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Completed NCT04726527 - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Completed NCT05537688 - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed NCT05525377 - Better Living With Non-memory-led Dementia N/A
Completed NCT02928848 - Transcranial Direct Current Stimulation for Primary Progressive Aphasia N/A
Completed NCT04939818 - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders